Kolon Corporation
002025.KS · Korea Exchange · KRW
11.100,00KRW
+140,00 (+1,28 %)Stand 10. Nov., 6:30
Kennzahlen
- Eröffnung
- 11.000,00
- Vortag
- 10.960,00
- Tagesspanne
- 10.850,00 – 11.130,00
- 52 Wochen
- 10.810,00 – 33.900,00
- Volumen
- 11.648
- Ø Volumen
- 5285
- Börsenwert
- 242,99 Mrd. KRW
- KGV
- -4,2
- Gewinn je Aktie (TTM)
- -4.637,39
- Dividendenrendite
- 2,8 %
- Beta
- 0,8
- Nächste Zahlen
- 18. Nov. 2026
Finanzen
| KRW | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 5,82 Bio. | 6,03 Bio. | 5,89 Bio. | 5,66 Bio. | 5,41 Bio. |
| Herstellungskosten | 5,4 Bio. | 5,66 Bio. | 5,4 Bio. | 4,97 Bio. | 4,75 Bio. |
| Bruttogewinn | 417,96 Mrd. | 366,57 Mrd. | 494,6 Mrd. | 685,49 Mrd. | 662,9 Mrd. |
| Forschung und Entwicklung | 10,25 Mrd. | 11,14 Mrd. | 4,24 Mrd. | 2,54 Mrd. | 1,58 Mrd. |
| Vertrieb und Verwaltung | 137,8 Mrd. | 139,08 Mrd. | 115,18 Mrd. | 109,29 Mrd. | 82,16 Mrd. |
| Operatives Ergebnis | −114,28 Mrd. | −89,55 Mrd. | 173,33 Mrd. | 317,51 Mrd. | 332,2 Mrd. |
| EBITDA | −20,18 Mrd. | 496,27 Mrd. | 221,14 Mrd. | 370,64 Mrd. | 313,38 Mrd. |
| Nettogewinn | −158,47 Mrd. | 170,31 Mrd. | 8,57 Mrd. | 159,88 Mrd. | 128,38 Mrd. |
| Gewinn je Aktie (verwässert) | -10.791,00 | 12.424,00 | 621,30 | 11.501,00 | 9.210,27 |
Bewertung
Letzte 12 Monate
- KGV
- -4,2
- Kurs-Umsatz-Verhältnis
- 0,0
- Kurs-Buchwert-Verhältnis
- 0,1
- PEG
- -0,2
- Bruttomarge
- 6,6 %
- Operative Marge
- 0,9 %
- Nettomarge
- −1,2 %
- Verschuldungsgrad
- 1,5
- EV/EBITDA
- 19,7
- Eigenkapitalrendite
- −3,8 %
- Kapitalrendite (ROIC)
- 0,7 %
- Free-Cashflow-Rendite
- −80,9 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 7,2 % | 6,1 % | 8,4 % | 12,1 % | 12,3 % |
| Operative Marge | −2,0 % | −1,5 % | 2,9 % | 5,6 % | 6,1 % |
| Nettomarge | −2,7 % | 2,8 % | 0,1 % | 2,8 % | 2,4 % |
| KGV | -4,6 | 1,1 | 27,4 | 1,9 | 3,5 |
| Kurs-Umsatz-Verhältnis | 0,1 | 0,0 | 0,0 | 0,1 | 0,1 |
| Kurs-Buchwert-Verhältnis | 0,5 | 0,1 | 0,2 | 0,3 | 0,6 |
| Verschuldungsgrad | 1,5 | 1,6 | 2,1 | 1,7 | 1,9 |
| Liquidität 3. Grades | 0,6 | 0,8 | 0,8 | 0,7 | 0,7 |
| Dividendenrendite | 0,9 % | 5,5 % | 4,3 % | 3,4 % | 2,1 % |
| Unternehmenswert | 3,17 Bio. | 2,5 Bio. | 2,15 Bio. | 1,8 Bio. | 1,8 Bio. |
| EV/EBITDA | -157,0 | 5,0 | 9,7 | 4,9 | 5,7 |
| Eigenkapitalrendite | −9,0 % | 10,3 % | 0,8 % | 14,6 % | 15,6 % |
| Kapitalrendite (ROIC) | −1,6 % | −1,2 % | 2,8 % | 6,6 % | 7,7 % |
| Free-Cashflow-Rendite | −9,3 % | −194,7 % | −76,5 % | 63,1 % | 44,0 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | −3,4 % | +2,3 % | +4,1 % | +4,6 % | +10,6 % |
| Bruttogewinn | +14,0 % | −25,9 % | −27,8 % | +3,4 % | +10,9 % |
| Operatives Ergebnis | −27,6 % | −151,7 % | −45,4 % | −4,4 % | +22,4 % |
| Nettogewinn | −193,0 % | +1.888,1 % | −94,6 % | +24,5 % | −14,0 % |
| Gewinn je Aktie | −186,9 % | +1.899,7 % | −94,6 % | +24,9 % | +4,2 % |
| Freier Cashflow | +79,1 % | −108,8 % | −194,7 % | −4,9 % | −34,9 % |
| Dividende je Aktie | −41,8 % | +5,4 % | −1,0 % | +7,2 % | +37,6 % |
Analysten
Einstufungen
Gerade nicht verfügbar.
Kursziel
Gerade nicht verfügbar.
Schätzungen
| FY 2026 | FY 2027 | |
|---|---|---|
| Umsatz (Ø) | 6,32 Bio. | 6,76 Bio. |
| Umsatz (Tief – Hoch) | 6,32 Bio. – 6,32 Bio. | 6,76 Bio. – 6,76 Bio. |
| Gewinn je Aktie (Ø) | 5.370,00 | 7.108,00 |
| Gewinn je Aktie (Tief – Hoch) | 5.370,00 – 5.370,00 | 7.108,00 – 7.108,00 |
| Analysten | 1 | 1 |
Quartalszahlen
Nächste Zahlen: 18. Nov. 2026| Aug. 2026 | Mai 2026 | Feb. 2026 | Nov. 2025 | Aug. 2025 | Mai 2025 | Feb. 2025 | Nov. 2024 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | – | – | – | – | – | – | – | – |
| Gewinn je Aktie · Tatsächlich | 1.435,89 | 892,95 | -17.590,51 | 281,02 | -2.676,08 | -1.170,79 | -3.915,69 | -2.875,03 |
| Abweichung | – | – | – | – | – | – | – | – |
| Umsatz · Tatsächlich | 1,67 Bio. | 1,52 Bio. | 1,5 Bio. | 1,41 Bio. | 1,5 Bio. | 1,45 Bio. | 1,54 Bio. | 1,54 Bio. |
Dividenden und Splits
| Ex-Tag | Zahltag | Betrag |
|---|---|---|
| 12. März 2026 | 6. Apr. 2026 | 600,00 |
| 27. Dez. 2024 | 3. Apr. 2025 | 600,00 |
| 27. Dez. 2023 | 5. Apr. 2024 | 600,00 |
| 28. Dez. 2022 | 6. Apr. 2023 | 600,00 |
| 29. Dez. 2021 | 7. Apr. 2022 | 600,00 |
| 29. Dez. 2020 | 7. Apr. 2021 | 550,00 |
| 27. Dez. 2019 | 3. Apr. 2020 | 550,00 |
| 27. Dez. 2018 | 26. Apr. 2019 | 550,00 |
| 27. Dez. 2017 | 20. Apr. 2018 | 550,00 |
| 28. Dez. 2016 | – | 550,00 |
| 29. Dez. 2015 | – | 550,00 |
| 29. Dez. 2014 | – | 550,00 |
Aktiensplits
- 1. Feb. 20107:25
Eigentümer
Institutionen
Gerade nicht verfügbar.
Insider-Geschäfte
–
Vergleichbare Unternehmen
001740.KSSK Networks Company Limited5.570,00+4,31 %
005880.KSKorea Line Corporation1.901,00+4,22 %
009415.KSTaeyoung Engineering & Construction Co.,Ltd.6.340,00−4,37 %
044490.KQTaewoong Co.,Ltd21.450,00+5,67 %
145990.KSSamyang Corporation43.650,00−0,46 %
145995.KSSamyang Corporation30.700,00−0,81 %
222080.KQSFA NEXEL Co., Ltd.6.790,00+7,27 %
383310.KQEcopro HN Co., Ltd.24.050,00+7,37 %
Über das Unternehmen
Kolon Corporation, established in 1957 and headquartered in Gwacheon, South Korea, operates as a diversified conglomerate. Its core activities include providing strategic support and management for its affiliated enterprises, licensing intellectual property, and offering market research and management consulting services globally. The company possesses extensive manufacturing capabilities, producing a broad spectrum of industrial and specialty materials. This includes textile reinforcements like tire cords and airbags, various films (polyester, nylon, and coated), and advanced products such as polyester spunbond, technical yarns, aramid products, and membranes. Kolon also manufactures DFR materials, overcoats, beads, and a diverse range of resins, including hydrocarbon, phenolic, epoxy, PU/TPU products, and glass-reinforced plastic (GRP) pipes. Furthermore, it is a key producer of nylon and polyester fibers, alongside a wide array of woven, knit, and functional fabrics. Beyond manufacturing, Kolon actively trades in steel, natural resources, and chemicals. Its construction and engineering divisions undertake residential, industrial plant, civil engineering, and environmental projects. The company also develops and supplies specialized automotive components like car seat modules, fabrics, and car mats, in addition to producing artificial turfs, polypropylene staple fibers, bicomponent staple fiber, GEONIC, Cuprus, HeaTex, and polyester filaments. In the leisure and real estate sectors, Kolon manages hotels, condominiums, and golf resorts, spearheads property development, and operates a shopping mall, a pet theme park, and unique themed toilets. Its significant presence in healthcare involves manufacturing over-the-counter medicines (such as the painkiller TRAMOL sustained relief), active pharmaceutical ingredients, and biopharmaceuticals like Tissuegene, complemented by a network of approximately 150 W-Store drugstores. Kolon's diversified portfolio further includes operating Sweet Meal cafés offering pastries and beverages, supplying antimicrobial products, and providing various resin types (PA, PBT, POM/base and compound). It also engages in hardware and software retail, delivers IT and business process outsourcing, and offers IT convergence services. The company is deeply involved in water-related businesses, encompassing sewage and wastewater treatment, the development of associated materials, systems, and equipment, and the operation of water treatment facilities, alongside industrial supply retail.
Führung
- Beomyong OhSecretary
- ByeongJin YuExecutive Director & Head of Ethics Management Office
- Byung-Deok AhnChief Executive Officer, President & Vice Chairman
- Kyu-Ho LeeVice Chairman, President & Chief Executive Officer
- YeongCheol KimMD & Personnel Manager
- YunSeok OkExecutive Director & Head of Business Management
- CEO
- Byung-Deok Ahn
- Mitarbeitende
- 91
- Hauptsitz
- Gwacheon-si, GY, KR
- Sektor
- Industrials
- Branche
- Conglomerates
- Börsengang
- 29. Sept. 2005
- Website
- kolon.com
Nachrichten
Gerade keine Nachrichten zu diesem Unternehmen.
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.